Compare ALUR & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALUR | COCP |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 15.3M |
| IPO Year | N/A | N/A |
| Metric | ALUR | COCP |
|---|---|---|
| Price | $1.48 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.25 | $6.00 |
| AVG Volume (30 Days) | ★ 109.6K | 98.5K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,208,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $0.90 |
| 52 Week High | $7.40 | $2.67 |
| Indicator | ALUR | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 45.84 |
| Support Level | $1.28 | $1.00 |
| Resistance Level | $1.57 | $1.19 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 32.31 | 11.36 |
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).